Rapid antipsychotic response with ziprasidone predicts subsequent acute manic/mixed episode remission JOURNAL OF PSYCHIATRIC RESEARCH Ketter, T. A., Agid, O., Kapur, S., Loebel, A., Siu, C. O., Romano, S. J. 2010; 44 (1): 8-14

Abstract

To assess rapid antipsychotic efficacy with oral ziprasidone monotherapy in bipolar acute manic/mixed episodes with psychotic features, and predictive value of rapid antipsychotic response for subsequent acute manic/mixed episode remission.Pooled analysis of two 3-week, randomized, double-blind, placebo-controlled trials of ziprasidone (40-160mg/d) in inpatients with bipolar I disorder, and a current manic or mixed episode, with (n=152) or without (n=246) psychotic features. Psychosis improvement was evaluated by change in SADS-C psychosis score (sum of delusions, hallucinations, and suspiciousness items). Rapid antipsychotic response (>or=50% decrease in SADS-C psychosis score by Day 4) and acute manic episode response and remission (endpoint >or=50% MRS decrease, and a MRS score

View details for DOI 10.1016/j.jpsychires.2009.07.006

View details for Web of Science ID 000274499100002

View details for PubMedID 19699488